コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 disposal rate (measured by hyperinsulinemic-euglycemic clamps).
2 utilization (determined by hyperinsulinemic-euglycemic clamps).
3 system was performed under hyperinsulinemic-euglycemic clamp.
4 esistance was assessed by a hyperinsulinemic-euglycemic clamp.
5 metabolism was evaluated by hyperinsulinemic-euglycemic clamp.
6 f glucose infusion during a hyperinsulinemic-euglycemic clamp.
7 -deoxyglucose uptake during hyperinsulinemic-euglycemic clamp.
8 c glucose production during hyperinsulinemic-euglycemic clamp.
9 that of the WT mice in the hyperinsulinemic-euglycemic clamp.
10 levels (near basal, 4x, or 16x) during a 5-h euglycemic clamp.
11 Insulin sensitivity was determined by euglycemic clamp.
12 cle glucose uptake during a hyperinsulinemic-euglycemic clamp.
13 ose uptake as measured by a hyperinsulinemic-euglycemic clamp.
14 sensitivity was measured by hyperinsulinemic-euglycemic clamp.
15 a traditional (i.e., 2-3 h) hyperinsulinemic-euglycemic clamp.
16 ivity (M/I) was assessed by hyperinsulinemic-euglycemic clamp.
17 ric characteristics and were studied using a euglycemic clamp.
18 tput than controls during a hyperinsulinemic-euglycemic clamp.
19 glucose production during a hyperinsulinemic-euglycemic clamp.
20 y glucose disposal during a hyperinsulinemic-euglycemic clamp.
21 Indians who had undergone a hyperinsulinemic-euglycemic clamp.
22 1.5 mU x kg(-1) x min (-1)) hyperinsulinemic-euglycemic clamp.
23 lucose utilization during a hyperinsulinemic-euglycemic clamp.
24 viduals before and during a hyperinsulinemic-euglycemic clamp.
25 cle glucose uptake during a hyperinsulinemic-euglycemic clamp.
26 rnight fast and after a 3-h hyperinsulinemic-euglycemic clamp.
27 tivity was measured using a hyperinsulinemic-euglycemic clamp.
28 in human muscle during the hyperinsulinemic euglycemic clamp.
29 nfused in conscious mice during a pancreatic euglycemic clamp.
30 sposal was assessed using a hyperinsulinemic-euglycemic clamp.
31 ivity, as measured with the hyperinsulinemic-euglycemic clamp.
32 cle glucose uptake during a hyperinsulinemic-euglycemic clamp.
33 ucose production during the hyperinsulinemic-euglycemic clamp.
34 nd increased rate of glucose disposal during euglycemic clamp.
35 sensitivity measured by the hyperinsulinemic-euglycemic clamp.
36 5-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.
37 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.
38 ween a baseline study and a hyperinsulinemic euglycemic clamp.
39 uscles at the baseline of a hyperinsulinemic-euglycemic clamp.
40 insulin tolerance tests and hyperinsulinemic-euglycemic clamps.
41 e tolerance test and during hyperinsulinemic-euglycemic clamps.
42 sensitivity was analyzed by hyperinsulinemic-euglycemic clamps.
43 K)-DGAT1 transgenic mice by hyperinsulinemic-euglycemic clamps.
44 s and glycogenolysis during hyperinsulinemic-euglycemic clamps.
45 Insulin sensitivity was measured using euglycemic clamps.
46 ucose disposal rates during hyperinsulinemic-euglycemic clamps.
47 glucose tolerance tests and hyperinsulinemic-euglycemic clamps.
48 mic clamps on day 2, and 3) hyperinsulinemic-euglycemic clamps.
49 as assessed with the use of hyperinsulinemic-euglycemic clamps.
50 istration of tracers during hyperinsulinemic-euglycemic clamping.
51 nd in wild-type mice during hyperinsulinemic-euglycemic clamping.
53 erinsulinemic (10 and 40 mU. m(-2). min(-1)) euglycemic clamp; (2) insulin effects on lipolysis by en
54 infusion (3 h), insulin was increased with a euglycemic clamp (3 mU x min(-1) x kg(-1)), and hindlimb
55 we infused either saline (n = 6) or insulin (euglycemic clamp, 3.0 mU x min(-1) x kg(-1), n = 9) into
56 s measured by a three-stage hyperinsulinemic-euglycemic clamp (4, 8, and 40 mU/m(2)/min) in 87 subjec
57 yperinsulinemic- (9 pmol x kg(-1) x min(-1)) euglycemic clamps (5.1 mmol/l), hypoglycemic clamps (2.9
58 /- 9.7 mg/dl) than during a hyperinsulinemic-euglycemic clamp (95.3 +/- 3.3 mg/dl), indicating mobili
59 naling in awake rats during hyperinsulinemic-euglycemic clamps after a lipid infusion with or without
61 ma Indians (P = 0.027) or a hyperinsulinemic-euglycemic clamp among 536 nondiabetic Native Americans
64 emale mice were assessed by hyperinsulinemic-euglycemic clamp analysis and indirect calorimetry and b
69 ld-type mice as assessed by hyperinsulinemic-euglycemic clamp analysis, consistent with a twofold inc
70 n type 1 diabetes using the hyperinsulinemic-euglycemic clamp and (31)P-MRS before, during, and after
75 ured GDR, fasting glucose, and FFAs during a euglycemic clamp and adipose tissue mass and distributio
76 d of each dietary period, a hyperinsulinemic-euglycemic clamp and an intravenous glucose tolerance te
77 sensitivity was measured by hyperinsulinemic-euglycemic clamp and ATP production in mitochondria isol
78 ntain euglycemia during the hyperinsulinemic-euglycemic clamp and could entirely be attributed to inc
79 sensitivity was measured by hyperinsulinemic-euglycemic clamp and insulin secretion by applying mathe
80 and glucose tolerance using hyperinsulinemic-euglycemic clamp and intravenous and oral glucose tolera
81 d insulin sensitivity using hyperinsulinemic-euglycemic clamp and muscle insulin receptor substrate a
83 were insulin sensitivity by hyperinsulinemic-euglycemic clamp and skeletal muscle mitochondrial capac
84 rom liver insulin resistance, as revealed by euglycemic clamps and hepatic insulin signaling determin
86 with a family history of type 2 diabetes had euglycemic clamps and muscle biopsies before and after a
89 glucose tolerance test and hyperinsulinemic euglycemic clamp) and imaging studies (MRI, DEXA, (1)H-N
90 (LPB) under postabsorptive (hypoinsulinemic-euglycemic clamp) and postprandial (hyperinsulinemic hyp
91 ), insulin sensitivity (via hyperinsulinemic-euglycemic clamps), and insulin secretion [via intraveno
92 tivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondria
93 nsitivity was measured by a hyperinsulinemic-euglycemic clamp, and skeletal muscle mitochondrial ATP
94 sensitivity, as measured by hyperinsulinemic-euglycemic clamp, and skeletal muscle mitochondrial func
96 in conscious rats during a hyperinsulinemic-euglycemic clamp as well as in adipocytes isolated from
97 on tomography (PET) imaging performed during euglycemic clamps at moderate hyperinsulinemia (40 mU x
98 nthropometric measures, FFAs, IR measured by euglycemic clamp, blood pressure, fasting serum lipids,
99 on insulin sensitivity (by hyperinsulinemic euglycemic clamp), body composition (by dual-energy X-ra
100 h a 40-mU x m(-2) x min(-1) hyperinsulinemic euglycemic clamp combined with a [6,6-(2)H(2)]-glucose i
102 ty were assessed using the hyperinsulinemic- euglycemic clamp combined with the glucose tracer techni
103 e treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiolabeled glucose to
106 hly insulin sensitive under hyperinsulinemic-euglycemic clamp conditions, eliminating insulin insensi
109 s glucose production during hyperinsulinemic-euglycemic clamp, consistent with induction of hepatic i
111 n action as assessed during hyperinsulinemic-euglycemic clamps did not differ between WT and PKC-thet
117 n sensitivity evaluated via hyperinsulinemic-euglycemic clamp, free fatty acids (FFAs) and FFA suppre
118 in infusion during low dose hyperinsulinemic-euglycemic clamp further lowered the glucose production
119 < 0.05) and negatively with hyperinsulinemic-euglycemic clamp glucose infusion rate (r = -0.28, P < 0
120 (IS; n = 10), determined by hyperinsulinemic-euglycemic clamp (>30% greater in IS compared with IR, P
121 ions and then during either hyperinsulinemic-euglycemic clamp (HE) (n = 10; 40 +/- 9 years, 8 female
123 tients underwent a two-step hyperinsulinemic-euglycemic clamp (HEC) with glucose tracer and labeled g
124 sitivity were assessed by a hyperinsulinemic euglycemic clamp (Human Actrapid 1.5 mU/min/kg) with an
125 Insulin sensitivity (S(I)) was measured by euglycemic clamp in 287 probands and their spouses (pare
126 ance gene, we performed the hyperinsulinemic-euglycemic clamp in a large family-based population of M
127 glucose metabolism during a hyperinsulinemic-euglycemic clamp in Acc2(-/-) and WT control mice fed a
130 ptake and metabolism during hyperinsulinemic-euglycemic clamp in control and muscle GLUT4 KO mice bef
132 glucose metabolism during a hyperinsulinemic-euglycemic clamp in Pref-1 transgenic and wild-type cont
133 signaling and action during hyperinsulinemic-euglycemic clamps in awake A-ZIP/F-1 (fatless), fat-tran
134 in these mice, we conducted hyperinsulinemic-euglycemic clamps in awake fatless and wild type litterm
138 tolerance tests (GTTs) and hyperinsulinemic-euglycemic clamps in mouse models of type 2 diabetes.
140 nfusion of insulin during a hyperinsulinemic-euglycemic clamp induced conspicuous ER stress in the 3-
142 mice demonstrate, using the hyperinsulinemic-euglycemic clamp, insulin insensitivity in muscle, liver
143 ol at baseline and during a hyperinsulinemic-euglycemic clamp), lipid oxidation (indirect calorimetry
144 on in isolated hepatocytes, hyperinsulinemic-euglycemic clamps, liver triglyceride content, and liver
145 rin-infusion (high FFA) and hyperinsulinemic-euglycemic clamping (low FFA) in a randomized crossover-
146 h contrasting levels of insulin sensitivity (euglycemic clamp measurements of insulin-dependent gluco
149 ion in IR was studied using hyperinsulinemic-euglycemic clamps on integrin alpha(2)beta(1)-null (itga
150 ect measures of insulin sensitivity, such as euglycemic clamp or insulin suppression test, in 2,764 E
152 infusion of insulin (3 mU. min(-1). kg(-1), euglycemic clamp) or saline in rat skeletal muscle in vi
153 legs before and after a 3-h hyperinsulinemic euglycemic clamp performed 3 h after a 45-min, one-legge
154 en dogs were studied during hyperinsulinemic-euglycemic clamp performed either at rest or combined wi
155 he following: 1) two 90-min hyperinsulinemic-euglycemic clamps plus naloxone infusion (control); 2) t
156 sal conditions and during a hyperinsulinemic-euglycemic clamp procedure (HECP), with and without conc
157 was evaluated by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable is
159 led tracer infusion and the hyperinsulinemic-euglycemic clamp procedure were used to assess skeletal
160 hr308) in 22 women during a hyperinsulinemic-euglycemic clamp procedure with and without concomitant
165 studies in the setting of a hyperinsulinemic-euglycemic clamp protocol revealed that chronically hype
166 a hyperinsulinemic (40 mU x m(-2) x min(-1))-euglycemic clamp (r = 0.63, P = 0.01), indicating that i
167 = 64] or insulin-resistant [IR] [n = 79] by euglycemic clamp) received four mixed meals over 14 h wi
168 y insulin resistance during hyperinsulinemic-euglycemic clamp resulting from >41% reductions in skele
169 ene expression analyses and hyperinsulinemic euglycemic clamp results suggest that CAR activation ame
172 Further investigation using hyperinsulinemic-euglycemic clamps revealed insulin resistance in MCKhLPL
174 of insulin resistance using hyperinsulinemic-euglycemic clamps revealed no significant differences in
177 s confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose infusion rate amo
179 scle insulin sensitivity by hyperinsulinemic-euglycemic clamp studies and muscle energetics by using
180 learance were quantified by hyperinsulinemic euglycemic clamp studies and pyruvate tolerance tests.
181 c insulin sensitivity using hyperinsulinemic-euglycemic clamp studies before and after surgery and co
183 lso observed during in vivo hyperinsulinemic euglycemic clamp studies during which Sur2(-/-) mice req
184 yruvate tolerance tests and hyperinsulinemic-euglycemic clamp studies established increased insulin s
186 se signaling factors during hyperinsulinemic-euglycemic clamp studies in nondiabetic subjects, subjec
198 sis on a high-fat diet, and hyperinsulinemic-euglycemic clamp studies revealed that insulin sensitivi
208 insulin tolerance tests and hyperinsulinemic-euglycemic clamp studies were performed with heterozygou
209 harvested before and after hyperinsulinemic-euglycemic clamp studies, at baseline and after 3-month
210 ncluding insulin tolerance, hyperinsulinemic-euglycemic clamp studies, insulin secretion in response
212 insulin sensitivity during hyperinsulinemic-euglycemic clamp studies, which was associated with incr
220 on day 15, and S(I) was measured by using a euglycemic clamp study (40 mU . m(-2) . min(-1)) on day
223 high exogenous insulin over the course of a euglycemic clamp study, indicating that hypoinsulinemia
224 of insulin sensitivity (3-h hyperinsulinemic-euglycemic clamp), substrate oxidation (indirect calorim
227 nsitivity measured with the hyperinsulinemic-euglycemic clamp technique and with plasma tumor necrosi
237 ous glucose tolerance test (four cohorts) or euglycemic clamp (three cohorts), and random-effects mod
238 h hyperinsulinemic (40 mU x m(-2) x min(-1))-euglycemic clamp to calculate insulin sensitivity and in
240 e were studied during a 2-h hyperinsulinemic-euglycemic clamp to determine the effect of tissue-speci
241 t we believe to be a novel hyperglucagonemic-euglycemic clamp to isolate an increment in glucagon lev
242 espite increased use of the hyperinsulinemic-euglycemic clamp to study insulin action in mice, the ef
243 glucose tolerance tests and hyperinsulinemic-euglycemic clamps to assess the role of the central GLP-
246 sis, we performed high-dose hyperinsulinemic-euglycemic clamps using [3-(3)H]-glucose in liver-specif
247 to assess IMCL content and hyperinsulinemic-euglycemic clamps using [6,6-(2)H(2)] glucose to assess
248 ithout insulin stimulation (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeoxyglucose scanning
249 emia, hyperlipidemia, and a hyperinsulinemic-euglycemic clamp) using positron emission tomography.
250 ontrols (n = 6) underwent a hyperinsulinemic-euglycemic clamp, VO2max test, dual-energy X-ray absorpt
252 cose infusion rate during a hyperinsulinemic-euglycemic clamp was increased by 50% in high-fat diet-f
254 Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected by pioglitazone
257 sing direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the relationships betwee
261 hyperinsulinemic (approximately 550 pmol/l) euglycemic clamps were conducted in conscious overnight-
263 At the end of the study, hyperinsulinemic-euglycemic clamps were performed and skeletal muscle (va
266 Basal insulin (0.2 mU x min(-1) x kg(-1)) euglycemic clamps were performed on fat-fed animals (n =
267 e-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were performed to assess beta-cell fun
270 -ribofuranoside (AICAR; 8 mg.kg(-1).min(-1))-euglycemic clamps were performed to elicit an increase i
272 ethionine restriction (MR), hyperinsulinemic-euglycemic clamps were used to examine the effect of the
273 er and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the tr
274 se, insulin levels, and insulin sensitivity (euglycemic clamp) were performed in adult offspring of p
275 in resistance assessed by a hyperinsulinemic-euglycemic clamp, which could mostly be attributed to in
276 stance was confirmed by the hyperinsulinemic euglycemic clamp, which showed attenuated inhibition of
277 g glucose disposal during a hyperinsulinemic-euglycemic clamp, while decreasing hepatic glucose produ
278 ensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glucose), and oral g
279 nsitivity was assessed by a hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-glucose infusion.
280 insulin sensitivity using a hyperinsulinemic euglycemic clamp with a glucose isotope tracer before an
281 perinsulinemia induced by a hyperinsulinemic euglycemic clamp with administered glucose in similar am
282 Twenty baboons received a hyperinsulinemic-euglycemic clamp with skeletal muscle and visceral adipo
283 hed Cs underwent a two-step hyperinsulinemic-euglycemic clamp with skeletal muscle biopsies and indir
284 nsitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tracer infusion) in
285 raded glucose infusion, and hyperinsulinemic-euglycemic clamp with stable-isotope-labeled tracer infu
288 ed-meal tolerance tests and hyperinsulinemic-euglycemic clamps with [6,6-(2)H2]glucose to assess gluc
289 mol/l), hypoglycemic clamps (2.9 mmol/l), or euglycemic clamps with a physiologic low-dose intravenou
291 wenty-one men underwent two hyperinsulinemic-euglycemic clamps with d-[6,6-(2)H2]glucose infusion to
292 on (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60% Vo(2max), plus na
294 mic-hypoglycemic and paired hyperinsulinemic-euglycemic clamps with infusion of 6,6-(2)H2-glucose and
296 o 5-h 80 mU. m(-2). min(-1) hyperinsulinemic-euglycemic clamps with measurement of glucose kinetics (
300 (1.5 mU . kg(-1) . min(-1)) hyperinsulinemic-euglycemic clamp, with an infusion of [6,6-(2)H(2)]gluco
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。